

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 5, 2006

Access Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware 0-9314 83-0221517

(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)

2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (214) 905-5100

Item 3.03 Material Modification to Rights of Security Holders

Access completed a one-for-five reverse stock split of the Company's
common stock par value \$0.01 per share on June 6, 2006.

Item 7.01 Regulation FD Disclosure

Access issued a press release on June 6, 2006, a copy of which is
attached as Exhibit 99.1 to this report and incorporated herein by this
reference, in which it announced the its one-for-five reverse stock
split of the Company's common stock.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

Access Pharmaceuticals, Inc.
(Registrant)

By: /s/ Stephen B. Thompson

Stephen B. Thompson
Vice President and

Chief Financial Officer

Dated June 8, 2006

EXHIBIT INDEX

Exhibit

Number Description

99.1 Press Release, dated June 8, 2006

ACCESS NEWS

Contact: Company
Stephen B. Thompson
Vice President & CFO
(214) 905-5100

Contact: Investor Relations
Donald C. Weinberger
Wolfe Axelrod Weinberger LLC
(212) 370-4500

ACCESS PHARMACEUTICALS IMPLEMENTS 1 FOR 5
REVERSE STOCK SPLIT

Dallas, TEXAS, June 5, 2006, ACCESS PHARMACEUTICALS, INC. (ACCP.OB) (formerly AKCA.OB) today announced a one for five reverse stock split. The reverse split will take effect and the shares will begin trading on a post-split basis at the opening of business on Monday, June 5, 2006. The Company's new ticker symbol is "ACCP" and the Company's common stock will be traded on the OTC Bulletin Board.

The shareholders at a meeting May 19, 2006 approved a five to one reverse stock split of the Company's common stock. After giving effect to the one for five reverse stock split, the Company will have approximately 3.5 million shares outstanding. Shareholders will be notified by American Stock Transfer & Trust Company, Access' stock transfer agent, regarding the process for receiving new share certificates.

The reverse split brings the number of shares outstanding and the share price to a level more consistent with companies of our size and stage of development.

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include AP5346, currently in Phase II clinical testing of patients with ovarian cancer and head and neck cancer, and our mucoadhesive liquid technology for the treatment of patients with mucositis. The Company also has other advanced drug delivery technologies including vitamin-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2005 and other reports filed by us with the Securities and Exchange Commission.

###